{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:33Z","timestamp":1792801653066,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00771-8","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:51:56Z","timestamp":1771055516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response"],"prefix":"10.1007","volume":"21","author":[{"given":"Bhavesh","family":"Mohan Lal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"16_suppl","key":"771_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e18503","volume":"40","author":"N Mankan","year":"2022","unstructured":"Mankan N, Nooka AK. Improvements in myeloma specific survival over the last two decades. J Clin Oncol. 2022;40(16_suppl):e18503\u2013e18503.","journal-title":"J Clin Oncol"},{"issue":"8","key":"771_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1001\/jamaoncol.2025.1394","volume":"11","author":"S Al Hadidi","year":"2025","unstructured":"Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Siegel ER, Bailey C, et al. Long-Term Follow-Up of patients with multiple myeloma treated on earlier total therapy protocols: A secondary analysis of 3 clinical trials. JAMA Oncol. 2025;11(8):910\u20135.","journal-title":"JAMA Oncol"},{"issue":"8","key":"771_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"771_CR4","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 27(4):335\u201347."},{"key":"771_CR5","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 31(5):408\u201321.","DOI":"10.1056\/NEJMoa2403407"},{"issue":"6","key":"771_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"24","key":"771_CR7","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, Donk NWCJ, van de, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell\u2013Redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232\u201344.","journal-title":"N Engl J Med"},{"issue":"8","key":"771_CR8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"key":"771_CR9","doi-asserted-by":"crossref","unstructured":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Oncol Off J Am Soc Clin Oncol. 2022 Sept 1;40(25):2889\u2013900.","DOI":"10.1200\/JCO.21.02228"},{"issue":"6","key":"771_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835\u201344.","journal-title":"Blood"},{"issue":"23","key":"771_CR11","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1200\/JCO.23.00934","volume":"42","author":"MC Pasquini","year":"2024","unstructured":"Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, et al. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and Lenalidomide maintenance are associated with Long-Term overall survival. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(23):2757\u201368.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"771_CR12","doi-asserted-by":"crossref","unstructured":"Shah Z, Khan I, Selene II, Waqar SHB, Khanam R, Abid Q, ul ain, et al. The association between minimal residual disease status and survival outcomes in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) patients: Systematic review. J Clin Oncol. 40(16suppl):e20009-20009.","DOI":"10.1200\/JCO.2022.40.16_suppl.e20009"},{"key":"771_CR13","doi-asserted-by":"crossref","unstructured":"Am BDNK, El L, U S et al. S, S M,. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol [Internet]. 2021 June [cited 2025 Oct 25];8(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34048681\/","DOI":"10.1016\/S2352-3026(21)00130-7"},{"issue":"3","key":"771_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ajh.27582","volume":"100","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Filippatos C, Ntanasis-Stathopoulos A, Malandrakis P, Kastritis E, Tsitsilonis OE, et al. Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials. Am J Hematol. 2025;100(3):427\u201338.","journal-title":"Am J Hematol"},{"issue":"6","key":"771_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2024.100252","volume":"24","author":"W Xu","year":"2024","unstructured":"Xu W, Liang X, Liu S, Yi X, Tian M, Yue T, et al. Dynamics of minimal residual disease and its clinical implications in multiple myeloma: a retrospective real-life analysis. Clin Med. 2024;24(6):100252.","journal-title":"Clin Med"},{"issue":"3","key":"771_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808\u201317.","journal-title":"Blood Adv"},{"issue":"11","key":"771_CR17","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(11):e890\u2013901.","journal-title":"Lancet Haematol"},{"key":"771_CR18","doi-asserted-by":"crossref","unstructured":"Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable Residual Disease\u2013Guided Therapy in Newly Diagnosed Myeloma. N Engl J Med. 30(5):425\u201337.","DOI":"10.1056\/NEJMoa2505133"},{"issue":"Supplement 1","key":"771_CR19","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1182\/blood-2023-189022","volume":"142","author":"FB Askeland","year":"2023","unstructured":"Askeland FB, Rasmussen AM, Lysen A, Hauk\u00e5s E, Eilertsen AL, Moksnes M, et al. Will survival improve by treating multiple myeloma patients at MRD relapse? The remnant study. Blood. 2023;142(Supplement 1):4755.","journal-title":"Blood"},{"issue":"1","key":"771_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14(1):170.","journal-title":"Blood Cancer J"},{"issue":"2","key":"771_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/07388551.2015.1128876","volume":"37","author":"A Adan","year":"2017","unstructured":"Adan A, Alizada G, Kiraz Y, Baran Y, Nalbant A. Flow cytometry: basic principles and applications. Crit Rev Biotechnol. 2017;37(2):163\u201376.","journal-title":"Crit Rev Biotechnol"},{"key":"771_CR22","unstructured":"Bataille R, J\u00e9go G, Robillard N, Barill\u00e9-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of many and multiple myelomas and of new targets for myeloma therapy. Haematologica. 91(9):1234\u201340."},{"key":"771_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00137","volume":"5","author":"N Robillard","year":"2014","unstructured":"Robillard N, Wuill\u00e8me S, Moreau P, B\u00e9n\u00e9 MC. Immunophenotype of normal and myelomatous plasma-cell subsets. Front Immunol. 2014;5:137.","journal-title":"Front Immunol"},{"issue":"1","key":"771_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","volume":"90","author":"J Flores-Montero","year":"2016","unstructured":"Flores-Montero J, de Tute R, Paiva B, Perez JJ, B\u00f6ttcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90(1):61\u201372.","journal-title":"Cytometry B Clin Cytom"},{"issue":"10","key":"771_CR25","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u2013103.","journal-title":"Leukemia"},{"issue":"8","key":"771_CR26","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales MB, et al. Measurable residual disease by Next-Generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784\u201392.","journal-title":"J Clin Oncol"},{"issue":"1","key":"771_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.15075","volume":"181","author":"Y Bai","year":"2018","unstructured":"Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181(1):11\u201326.","journal-title":"Br J Haematol"},{"issue":"10","key":"771_CR28","first-page":"1365","volume":"90","author":"ME Sarasquete","year":"2005","unstructured":"Sarasquete ME, Garc\u00eda-Sanz R, Gonz\u00e1lez D, Mart\u00ednez J, Mateo G, Mart\u00ednez P, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365\u201372.","journal-title":"Haematologica"},{"key":"771_CR29","doi-asserted-by":"crossref","unstructured":"Takamatsu H. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. J Clin Med. 2017(10):91.","DOI":"10.3390\/jcm6100091"},{"issue":"2","key":"771_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2013.217","volume":"28","author":"N Puig","year":"2014","unstructured":"Puig N, Sarasquete ME, Balanzategui A, Mart\u00ednez J, Paiva B, Garc\u00eda H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391\u20137.","journal-title":"Leukemia"},{"key":"771_CR31","doi-asserted-by":"publisher","first-page":"932852","DOI":"10.3389\/fonc.2022.932852","volume":"12","author":"V Ferla","year":"2022","unstructured":"Ferla V, Antonini E, Perini T, Farina F, Masottini S, Malato S, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy. Front Oncol. 2022;12:932852.","journal-title":"Front Oncol"},{"key":"771_CR32","doi-asserted-by":"crossref","unstructured":"Oliva S, Genuardi E, Paris L, D\u2019Agostino M, Rogers J, Rota-Scalabrini D, et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. EClinicalMedicine. 60:102016.","DOI":"10.1016\/j.eclinm.2023.102016"},{"issue":"10","key":"771_CR33","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.clml.2019.09.005","volume":"19","author":"H Avet-Loiseau","year":"2019","unstructured":"Avet-Loiseau H, Bene MC, Wuilleme S, Corre J, Attal M, Arnulf B, et al. Concordance of Post-consolidation minimal residual disease rates by multiparametric flow cytometry and Next-generation sequencing in CASSIOPEIA. Clin Lymphoma Myeloma Leuk. 2019;19(10):e3\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"771_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333.","journal-title":"Mayo Clin Proc"},{"key":"771_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clinbiochem.2017.09.007","volume":"51","author":"AKY Tsui","year":"2018","unstructured":"Tsui AKY, Thomas D, Hunt A, Estey M, Christensen CL, Higgins T, et al. Analytical sensitivity and diagnostic performance of serum protein electrophoresis on the HYDRAGEL 30 PROTEIN(E) \u03b21-\u03b22 Sebia Hydrasys system. Clin Biochem. 2018;51:80\u20134.","journal-title":"Clin Biochem"},{"issue":"4","key":"771_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1515\/cclm-2019-1105","volume":"58","author":"JFM Jacobs","year":"2020","unstructured":"Jacobs JFM, Turner KA, Graziani MS, Frinack JL, Ettore MW, Tate JR, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med. 2020;58(4):547\u201359.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"771_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","volume":"66","author":"M Zajec","year":"2020","unstructured":"Zajec M, Langerhorst P, VanDuijn MM, Gloerich J, Russcher H, van Gool AJ, et al. Mass spectrometry for Identification, Monitoring, and minimal residual disease detection of M-Proteins. Clin Chem. 2020;66(3):421\u201333.","journal-title":"Clin Chem"},{"issue":"2","key":"771_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","volume":"11","author":"DL Murray","year":"2021","unstructured":"Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report. Blood Cancer J. 2021;11(2):24.","journal-title":"Blood Cancer J"},{"issue":"21","key":"771_CR39","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/rcm.7314","volume":"29","author":"DR Barnidge","year":"2015","unstructured":"Barnidge DR, Krick TP, Griffin TJ, Murray DL. Using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry to detect monoclonal Immunoglobulin light chains in serum and urine. Rapid Commun Mass Spectrom RCM. 2015;29(21):2057\u201360.","journal-title":"Rapid Commun Mass Spectrom RCM"},{"issue":"10","key":"771_CR40","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","volume":"62","author":"JR Mills","year":"2016","unstructured":"Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, et al. Comprehensive assessment of M-proteins using Nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62(10):1334\u201344.","journal-title":"Clin Chem"},{"issue":"10","key":"771_CR41","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1373\/clinchem.2015.253781","volume":"62","author":"MC Kohlhagen","year":"2016","unstructured":"Kohlhagen MC, Barnidge DR, Mills JR, Stoner J, Gurtner KM, Liptac AM, et al. Screening method for M-proteins in serum using Nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62(10):1345\u201352.","journal-title":"Clin Chem"},{"issue":"12","key":"771_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","volume":"9","author":"D Murray","year":"2019","unstructured":"Murray D, Kumar SK, Kyle RA, Dispenzieri A, Dasari S, Larson DR, et al. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal Immunoglobulin rapid accurate mass measurement. Blood Cancer J. 2019;9(12):102.","journal-title":"Blood Cancer J"},{"issue":"8","key":"771_CR43","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ajh.24772","volume":"92","author":"P Milani","year":"2017","unstructured":"Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92(8):772\u20139.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"771_CR44","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1182\/blood-2023-189850","volume":"142","author":"T Kubicki","year":"2023","unstructured":"Kubicki T, Dytfeld D, Wrobel T, Jamroziak K, Robak P, Czyz J, et al. Longitudinal assessment of minimal residual disease (MRD) in the ATLAS randomized phase 3 trial of post-transplant treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide (R) alone in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2023;142(Supplement 1):4715.","journal-title":"Blood"},{"issue":"9","key":"771_CR45","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1182\/blood.2024025189","volume":"144","author":"AJ Yee","year":"2024","unstructured":"Yee AJ. An ATLAS to map MRD with peripheral blood. Blood. 2024;144(9):919\u201320.","journal-title":"Blood"},{"key":"771_CR46","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1182\/blood-2023-184837","volume":"142","author":"N Puig","year":"2023","unstructured":"Puig N, Agullo C, Contreras T, Paiva B, Cedena MT, Rosi\u00f1ol L, et al. Analysis of peripheral blood and bone marrow residual disease dynamics during intensive treatment and maintenance in patients with multiple myeloma included in the GEM12MENOS65 and GEM14MAIN clinical trials. Blood. 2023;142:3324.","journal-title":"Blood"},{"issue":"1","key":"771_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","volume":"13","author":"EK Mai","year":"2023","unstructured":"Mai EK, Huhn S, Miah K, Poos AM, Scheid C, Weisel KC, et al. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer J. 2023;13(1):1.","journal-title":"Blood Cancer J"},{"issue":"1","key":"771_CR48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","volume":"62","author":"HR Bergen","year":"2016","unstructured":"Bergen HR, Dasari S, Dispenzieri A, Mills JR, Ramirez-Alvarado M, Tschumper RC, et al. Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration. Clin Chem. 2016;62(1):243\u201351.","journal-title":"Clin Chem"},{"issue":"7","key":"771_CR49","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jmoldx.2020.04.002","volume":"22","author":"CO Martins","year":"2020","unstructured":"Martins CO, Huet S, Yi SS, Ritorto MS, Landgren O, Dogan A, et al. Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma. J Mol Diagn. 2020;22(7):901\u201311.","journal-title":"J Mol Diagn"},{"key":"771_CR50","doi-asserted-by":"crossref","unstructured":"Liyasova M, McDonald Z, Taylor P, Gorospe K, Xu X, Yao C, et al. A Personalized Mass Spectrometry\u2013Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). Clin Cancer Res 2021 Sept. 15(18):5028\u201337.","DOI":"10.1158\/1078-0432.CCR-21-0649"},{"issue":"3","key":"771_CR51","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","volume":"17","author":"M Zajec","year":"2018","unstructured":"Zajec M, Jacobs JFM, Groenen PJTA, de Kat Angelino CM, Stingl C, Luider TM, et al. Development of a targeted Mass-Spectrometry serum assay to quantify M-Protein in the presence of therapeutic monoclonal antibodies. J Proteome Res. 2018;17(3):1326\u201333.","journal-title":"J Proteome Res"},{"issue":"4","key":"771_CR52","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","volume":"28","author":"FA Bonilla","year":"2008","unstructured":"Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28(4):803\u201319.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"24","key":"771_CR53","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1182\/blood.2019002610","volume":"134","author":"L Sanoja-Flores","year":"2019","unstructured":"Sanoja-Flores L, Flores-Montero J, Puig N, Contreras-Sanfeliciano T, Pontes R, Corral-Mateos A, et al. Blood monitoring of Circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134(24):2218\u201322.","journal-title":"Blood"},{"issue":"12","key":"771_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.117","volume":"6","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, et al. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 2016;6(12):e512\u2013e512.","journal-title":"Blood Cancer J"},{"key":"771_CR55","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Stevenson PA, Libby EN, Becker PS, Coffey DG, Green DJ et al. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy. Biol Blood Marrow Transplant. 2018 July 1;24(7):1386\u201391.","DOI":"10.1016\/j.bbmt.2018.02.017"},{"issue":"8","key":"771_CR56","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood.2025029234","volume":"146","author":"M Lasa","year":"2025","unstructured":"Lasa M, Gonzalez C, Notarfranchi L, Zherniakova A, Alignani D, Burgos L, et al. Ultrasensitive detection of Circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment. Blood. 2025;146(8):964\u201370.","journal-title":"Blood"},{"key":"771_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852573","volume":"12","author":"X Ye","year":"2022","unstructured":"Ye X, Li W, Zhang L, Yu J. Clinical significance of circulating cell-free DNA detection in multiple myeloma: a meta-analysis. Front Oncol. 2022;12:852573.","journal-title":"Front Oncol"},{"key":"771_CR58","unstructured":"Personalized. ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma. - ASCO [Internet]. [cited 2025 Dec 28]. Available from: https:\/\/www.asco.org\/abstracts-presentations\/195455"},{"issue":"Supplement 1","key":"771_CR59","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood-2023-182410","volume":"142","author":"BA Derman","year":"2023","unstructured":"Derman BA, Kubicki T, Simmons H, Afrough A, Zonder JA, Grinblatt DL, et al. Early peripheral blood minimal residual disease status by NGS in patients with newly diagnosed multiple myeloma (MM) on a phase 2 trial receiving elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd). Blood. 2023;142(Supplement 1):1982.","journal-title":"Blood"},{"key":"771_CR60","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-1-4939-7778-9_14","volume":"1768","author":"D Drandi","year":"2018","unstructured":"Drandi D, Ferrero S, Ladetto M. Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders. Methods Mol Biol Clifton NJ. 2018;1768:229\u201356.","journal-title":"Methods Mol Biol Clifton NJ"},{"issue":"5","key":"771_CR61","doi-asserted-by":"publisher","first-page":"e0285696","DOI":"10.1371\/journal.pone.0285696","volume":"18","author":"A Marx","year":"2023","unstructured":"Marx A, Osv\u00e1th M, Szikora B, Pipek O, Csabai I, Nagy \u00c1, et al. Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes\u2013a feasibility study. PLoS ONE. 2023;18(5):e0285696.","journal-title":"PLoS ONE"},{"key":"771_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-0716-2115-8_5","volume":"2453","author":"ID Starza","year":"2022","unstructured":"Starza ID, Eckert C, Drandi D, Cazzaniga G, EuroMRD Consortium. Minimal residual disease analysis by monitoring immunoglobulin and T-cell receptor gene rearrangements by quantitative PCR and droplet digital PCR. Methods Mol Biol Clifton NJ. 2022;2453:79\u201389.","journal-title":"Methods Mol Biol Clifton NJ"},{"issue":"3","key":"771_CR63","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3324\/haematol.2023.283831","volume":"109","author":"S Mithraprabhu","year":"2024","unstructured":"Mithraprabhu S, Reynolds J, Quach H, Horvath N, Kerridge I, Khong T, et al. Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients. Haematologica. 2024;109(3):974\u20138.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"771_CR64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood-2024-204426","volume":"144","author":"P Bajaj","year":"2024","unstructured":"Bajaj P, Landgren O, Green DJ, Coffey DG. Circulating tumor DNA as a minimally invasive predictor of early relapse in multiple myeloma. Blood. 2024;144(Supplement 1):252.","journal-title":"Blood"},{"key":"771_CR65","unstructured":"Du J. Application of Ultrasensitive Chromosomal Aneuploidy Detection (UCAD) as a Surrogate Biomarker of Minimal Residual Diseases for Multiple Myeloma Patients [Internet]. clinicaltrials.gov; 2019 Nov [cited 2025 Oct 28]. Report No.: NCT04122092. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04122092"},{"key":"771_CR66","doi-asserted-by":"publisher","first-page":"1103797","DOI":"10.3389\/fonc.2023.1103797","volume":"13","author":"AD Johnston","year":"2023","unstructured":"Johnston AD, Ross JP, Ma C, Fung KYC, Locke WJ. Epigenetic liquid biopsies for minimal residual disease, what\u2019s around the corner? Front Oncol. 2023;13:1103797.","journal-title":"Front Oncol"},{"key":"771_CR67","unstructured":"An G, Circulating Tumor DNA. Methylation Sequencing for Multiple Myeloma Minimal Residual Disease Detection and Clonal Evolution Monitoring [Internet]. clinicaltrials.gov; 2022 Oct [cited 2025 Oct 27]. Report No.: NCT05578625. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05578625"},{"issue":"24","key":"771_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415691","volume":"23","author":"A Matera","year":"2022","unstructured":"Matera A, Marella A, Maeda A, Da Vi\u00e0 MC, Lazzaroni F, Fabris S, et al. Single-cell RNA sequencing for the detection of clonotypic V(D)J rearrangements in multiple myeloma. Int J Mol Sci. 2022;23(24):15691.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"771_CR69","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00277-025-06241-0","volume":"104","author":"Y Xiang","year":"2025","unstructured":"Xiang Y, Sun G, Tian L, Xiang P, Xie C. Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion? Ann Hematol. 2025;104(2):895\u2013912.","journal-title":"Ann Hematol"},{"issue":"3","key":"771_CR70","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27(3):491\u2013503.","journal-title":"Nat Med"},{"issue":"825","key":"771_CR71","doi-asserted-by":"publisher","first-page":"eadu0114","DOI":"10.1126\/scitranslmed.adu0114","volume":"17","author":"J Guo","year":"2025","unstructured":"Guo J, Li Y, Yan Z, Li Q, Liu Z, Li Z, et al. Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation. Sci Transl Med. 2025;17(825):eadu0114.","journal-title":"Sci Transl Med"},{"key":"771_CR72","doi-asserted-by":"crossref","unstructured":"Wang Y, Peng Y, Yang C, Xiong D, Wang Z, Peng H et al. Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets. Cell Death Dis. 2024 Sept 14;15(9):672.","DOI":"10.1038\/s41419-024-07027-4"},{"issue":"1","key":"771_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13578-023-00971-2","volume":"13","author":"M Chen","year":"2023","unstructured":"Chen M, Wan Y, Li X, Xiang J, Chen X, Jiang J, et al. Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma. Cell Biosci. 2023;13(1):19.","journal-title":"Cell Biosci"},{"key":"771_CR74","doi-asserted-by":"crossref","unstructured":"Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD et al. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 Sept 1;8(9):1278\u201386.","DOI":"10.1001\/jamaoncol.2022.2424"},{"issue":"18","key":"771_CR75","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142(18):1518\u201328.","journal-title":"Blood"},{"issue":"10","key":"771_CR76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","volume":"10","author":"A Medina","year":"2020","unstructured":"Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M, et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10(10):108.","journal-title":"Blood Cancer J"},{"issue":"7","key":"771_CR77","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/COC.0000000000001197","volume":"48","author":"B Chen","year":"2025","unstructured":"Chen B, Pan Q, Dong Y. Advancing MRD detection in multiple myeloma: technologies, applications, and future perspectives. Am J Clin Oncol. 2025;48(7):376.","journal-title":"Am J Clin Oncol"},{"key":"771_CR78","unstructured":"Memorial Sloan Kettering Cancer Center, Single-Arm A. Prospective Study of Maintenance Therapy Cessation for Patients With Multiple Myeloma in Sustained MRD-Negative Remissions [Internet]. clinicaltrials.gov; 2025 Oct [cited 2025 Oct 28]. Report No.: NCT04221178. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04221178"},{"key":"771_CR79","unstructured":"University of Chicago. A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple Myeloma (MRD2STOP) [Internet]. clinicaltrials.gov; 2025 July [cited 2025 Oct 28]. Report No.: NCT04108624. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04108624"},{"key":"771_CR80","unstructured":"Janssen R, Development LLCA. Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant [Internet]. clinicaltrials.gov; 2025 Oct [cited 2025 Oct 28]. Report No.: NCT03901963. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03901963"},{"key":"771_CR81","unstructured":"University of Chicago. Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma [Internet]. clinicaltrials.gov; 2025 Jan [cited 2025 Oct 28]. Report No.: NCT02659293. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02659293"},{"key":"771_CR82","unstructured":"Almaguer DG. Low-dose Teclistamab As Consolidation in the First-line Treatment of Patients with Newly Diagnosed Multiple Myeloma. [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Oct 28]. Report No.: NCT06758375. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06758375"},{"key":"771_CR83","unstructured":"Costa LJ. MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Oct 28]. Report No.: NCT05231629. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05231629"},{"key":"771_CR84","unstructured":"Study Details | MInimal. Residual Disease Adapted Strategy | ClinicalTrials.gov [Internet]. [cited 2024 Aug 11]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04934475"},{"key":"771_CR85","unstructured":"PETHEMA Foundation. An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Oct 28]. Report No.: NCT05849610. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05849610"},{"key":"771_CR86","unstructured":"Institute of Hematology & Blood Diseases Hospital, Prospective CA, Open-Label. Single-Center Clinical Study of a Fully Immunotherapy-Based Strategy Driven by MRD-Guided Dynamic Risk Stratification in Transplant-Ineligible Newly Diagnosed Multiple Myeloma [Internet]. clinicaltrials.gov; 2025 July [cited 2025 Oct 28]. Report No.: NCT07106736. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07106736"},{"key":"771_CR87","unstructured":"Bar N, Improving MRD. Negativity Rates in Newly Diagnosed Multiple Myeloma Patients: a Response-adaptive Approach of Consolidation With One or Two Bispecific T-cell Engagers Against GPRC5D or BCMA [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Oct 28]. Report No.: NCT06993675. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06993675"},{"key":"771_CR88","unstructured":"Stichting European Myeloma Network. A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy [Internet]. clinicaltrials.gov; 2024 Dec [cited 2025 Oct 28]. Report No.: NCT03710603. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03710603"},{"key":"771_CR89","unstructured":"Washington University School of Medicine. Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Oct 28]. Report No.: NCT06483100. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06483100"},{"key":"771_CR90","unstructured":"University of Arkansas. A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR) [Internet]. clinicaltrials.gov; 2025 July [cited 2025 Oct 28]. Report No.: NCT07029776. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07029776"},{"key":"771_CR91","unstructured":"Schjesvold FH. The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Oct 28]. Report No.: NCT04513639. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04513639"},{"key":"771_CR92","unstructured":"Development Innovations SCRI. LLC. Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER) [Internet]. clinicaltrials.gov; 2025 Aug [cited 2025 Oct 28]. Report No.: NCT06974786. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06974786"},{"key":"771_CR93","unstructured":"SWOG Cancer Research Network. S1803, Phase III Study of Daratumumab\/rHuPH20(NSC-810307)\u2009+\u2009Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) [Internet]. clinicaltrials.gov;2025 Sept [cited 2025 Oct 28]. Report No.: NCT04071457. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04071457."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00771-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:03:30Z","timestamp":1771059810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00771-8","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}